Matthew D. Breyer, MD, FASN
Matthew D. Breyer, CSO BioTDR Lead Generation Eli Lilly: Dr. Breyer received his M.D from Harvard Medical School in 1979, and is board certified in Internal Medicine and Nephrology. He was faculty in the division of Nephrology Vanderbilt University Medical School for twenty one years where he ran a lab which utilized transgenic mouse models to study the pathophysiology of hypertension and diabetic kidney disease. Dr. Breyer held numerous NIH and VA grants and headed the nephropathy sub-group of the NIH Animal Models of Diabetic Complications Consortium (AMDCC) from 2001-2006. As a result of his interest in developing treatments for diabetic nephropathy he moved to Eli Lilly in 2007 to oversee a program to develop bio-therapeutics for diabetic kidney disease. In 2009 he was appointed to his current position at Eli Lilly as the Chief Scientific Officer for lead generation in Biotechnology Discovery Research where he oversees target identification and development of biologics for metabolic, neurologic, and musculoskeletal diseases, oncology in addition to chronic kidney disease.
KHI Member support provided by: Eli Lilly and Company